NCT06763835Active, not recruiting
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis
Development and Validation of Diagnostic and Prognostic Model of Acute Coronary Syndrome Caused by Plaque Erosion Using Novel Serum Biomarkers
Source: ClinicalTrials.gov · Last updated 14 Jan 2025
Brief summary (registry, in English)
The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is • Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 301 (actual)
- First submitted
- 2 Jan 2025
- Start date
- 1 Feb 2023
- Primary completion date
- 30 Jul 2024
- Lead sponsor
- Xuebo Liu
- Diseases
- Coronary artery disease
- NCT number
- NCT06763835
What you commit to
- Study type: Observational
- Participants enrolled: 301
- From 1 Feb 2023 to the primary completion date, 30 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- prior coronary artery bypass grafting,
Other illness
- patients with corornary stent thrombosis
- patients with left main coronary disease
- patients with congestive heart failure
- patients with life-threatening arrhythmia
- patients with thrombocytopenia patients with significant hepatic or renal impairment
- patients with septicemia, leukopenia, active inflammatory or malignant disease
Age
- patients younger than 18 years or older than 85 years
Other
- patients in cardiogenic shock
- other factors compromising high-quality optical coherence tomography (OCT) imaging (e.g., severe vessel tortuosity or calcification, persistent no-reflow, lesions in distal segments, or an indeterminate culprit lesion)
- Individuals unable to provide informed consent were also excluded.
Who the study is looking for
- people presenting with an acute coronary syndrome (ACS)-either non-ST-segment elevation myocardial infarction (NSTE-ACS); or ST-segment elevation myocardial infarction (STE-ACS), and subsequently underwent emergent coronary angiography followed by percutaneous coronary intervention (PCI). Culprit leisions were tested using optical coheren tomograpgy and pathological diagnosis(PE OR PR) were validated by 2 independent experienced core lab members.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongj University School of Medicine, 200333, Shanghai ,China Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.